Hamden, CT, United States of America

Robert H Stoffel


Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2000-2002

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Inventor Spotlight: Robert H. Stoffel

Introduction

Robert H. Stoffel is an accomplished inventor based in Hamden, Connecticut, known for his significant contributions to the field of pharmacology. With two patents to his name, Stoffel has made strides in developing innovative compounds aimed at addressing critical health issues, particularly in the realm of appetite regulation and weight loss.

Latest Patents

Stoffel's latest patents focus on two primary innovations: "NPY antagonists: spiroisoquinolinone derivatives" and "Imidazolone anorectic agents: II. phenyl derivatives." These patents detail a series of non-peptidergic antagonists of Neuropeptide Y (NPY), synthesized as phenyl derivatives of imidazolone compounds. As antagonists of NPY-induced feeding behavior, these innovative compounds are expected to serve as effective anorexiant agents, aiding in weight loss and treatment of eating disorders.

Career Highlights

Stoffel is currently employed at Bristol-Myers Squibb Company, a leading global biopharmaceutical firm. His work at the company has centered around the development of groundbreaking treatments that address various health conditions. With his focus on pharmacological innovations, Stoffel has been instrumental in advancing new therapeutic approaches that could benefit countless individuals struggling with eating disorders.

Collaborations

Throughout his career, Robert H. Stoffel has collaborated with various esteemed colleagues, including Graham S. Poindexter and Ildiko Antal. These partnerships have fostered a dynamic research environment that emphasizes innovation and the pursuit of effective solutions to complex medical challenges.

Conclusion

Robert H. Stoffel exemplifies the spirit of innovation in the pharmacological landscape. Through his development of NPY antagonists and imidazolone anorectic agents, he continues to contribute valuable advancements that may revolutionize approaches to weight loss and eating disorder treatment in the future. His commitment to research and collaboration stands as a testament to the potential impact of dedicated inventors in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…